NCT04702802已完成不适用
Clinical Study to Evaluate the Safety of the Viscoelastic Substance PRO-149 When Used as a Device During Phacoemulsification and Intraocular Lens Implantation in Patients With Age-related Cataract, Compared to Healon® EndoCoat.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Change in Corneal Endothelial Cell Count
研究概览
简要总结
Pilot, controlled, parallel group, open, randomized clinical trial to evaluate the safety of the viscoelastic substance PRO-149 (sodium hyaluronate 3%) after trans-surgical administration as a device in performing phacoemulsification and intraocular lens implantation in 36 patients with age-related cataract, compared to Healon® EndoCoat (sodium hyaluronate 3%).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 49 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 49 years old
- •Age-related cataract diagnosis which requires phacoemulsification and monofocal intraocular lens implantation
- •Being capable of voluntarily grant a signed informed consent.
- •Being willing and able to meet the requirements of the study such as attending programmed visits, treatment plan and other study procedures.
- •Willingness to be subjected to phacoemulsification and monofocal intraocular lens implantation.
- •An anterior chamber depth of ≥ 2.8 mm measured through IOL Master®.
- •Pre-surgical cardiologic evaluation that validates the patient's eligibility to surgical procedure, including supporting studies: blood biometry, blood chemistry, clotting time, and electrocardiogram. This evaluation must not exceed 45 days prior to the date of signing of the informed consent.
排除标准
- •Previous history of any systemic medical affliction that prevents a patient from being considered eligible for the surgical procedure under sedation and topical anesthesia.
- •Previous history of Diabetes Mellitus with A1C ≥ 6.5% (48 mmol/mol) or glucose levels (after no caloric ingestion for ≥ 8 hours) of ≥ 126 mg/dL (7.0 mmol/L).
- •Poorly controlled systemic arterial hypertension, defined as a value ≥ 140/90 despite the use of three antihypertensive drugs (one of them a diuretic) at maximum dose.
- •Previous history of ocular diseases that may limit the BCVA, or that may reactivate or worsen due to the surgical procedure or due to the use of topical steroids (por example, retinal detachment, macular degeneration, degenerative myopia, proliferative diabetic retinopathy, diabetic macular edema, optic neuritis, uveitis or any other kind of ocular inflammation, glaucoma, intraocular hypertension, corneal dystrophies or ectasias, history of ocular herpes or zoster).
- •Active ocular infection
- •Pseudoexfoliation syndrome in the eye to withstand surgery, or any other such zonular compromise.
- •Pharmacological mydriasis < 6 mm.
- •Any congenital anomalies in the eye to withstand surgery.
- •Any alteration that prevents a reliable Goldmann tonometry in the eye to withstand surgery.
- •IOP >21mmHg in the eye to withstand surgery, or previous history of IOP > 21 mmHg after topical steroid use.
- •Corneal endothelial cell count < 1500 cells/mm2 in the eye to withstand surgery.
- •Previous history of corneal or intraocular surgery.
- •Planned multiple procedures during cataract surgery (for example, trabeculectomy, keratotomies, etc)
- •Previous history of ocular trauma in the eye to withstand surgery (including surgical procedures)
- •Having one functional eye.
- •Having participated in clinical trials within 30 days prior to signing this study's informed consent form.
- •Having participated previously in this study.
- •Previous history of drug addiction within the last 2 years prior to signing this study's informed consent form.
- •Having a previous history of any ophthalmological surgical procedure, within the last 3 months prior to the informed consent signing date.
- •Having any kind of programed surgery during the period of this study.
- •Being or having any immediate family members (spouse, parent/legal tutor, sibling or child) who work either in the investigation center or for the sponsor of this study.
结局指标
主要结局
Change in Corneal Endothelial Cell Count
时间窗: Days: -15 (±2) (eligibility visit), and 29 (±2) (final visit)
By means of specular microscopy, endothelial cell count will take place. Density expressed in cells/mm2 will be recorded. Normal density varies according to age, but an average of 1500 - 3500 cells/mm2 (age 40 to 90) has been described.
Change in Intraocular Pressure (IOP)
时间窗: Days: -15 (±2) (eligibility visit [EV]), 1 (first safety evaluation visit [V1]), 8 (±2) (second safety evaluation visit [V2]), and 29 (±2) (final visit [FV])
Measured through Goldman tonometer in milligrams of mercury (mmHg). After instillation of topical anesthetic (tetracaine 0.5%) and fluorescein stain, IOP is evaluated twice to obtain an average to be recorded. Normal values are considered between 10 and 21 mmHg.
次要结局
- Number of Participants Presenting Adverse Events(From Day -15 (±2) (eligibility visit) through Day 29 (±2) (final visit))
- Change in Central Corneal Thickness(Days: -15 (±2) (eligibility visit [EV]), and 29 (±2) (final visit [FV]))
- Change in Anterior Chamber Cellularity(Days: -15 (±2) (eligibility visit [EV]), 1 (first safety evaluation visit [V1]), 8 (±2) (second safety evaluation visit [V2]), and 29 (±2) (final visit [FV]))
- Change in Anterior Chamber Flare(Days: -15 (±2) (eligibility visit [EV]), 1 (first safety evaluation visit [V1]), 8 (±2) (second safety evaluation visit [V2]), and 29 (±2) (final visit [FV]))
- Change in Best Corrected Visual Acuity (BCVA)(Days: -15 (±2) (eligibility visit [EV]), 1 (first safety evaluation visit [V1]), 8 (±2) (second safety evaluation visit [V2]), and 29 (±2) (final visit [FV]))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Pilot Clinical Investigation Evaluating the Safety and Performance of RGn550 in Treating Sportspeople Suffering From Acute Concussion SyndromeAcute Concussion SyndromeNCT05647304REGEnLIFE SAS50
已完成
不适用
The RA PROTECTION StudyRheumatoid ArthritisNCT04306744Nesos Corp162
已完成
1 期
A Pilot Study to Evaluate Safety and Efficacy of CigRx™ in SmokersSmokingTobacco Use DisorderNCT01262170Rock Creek Pharmaceuticals, Inc.109
已完成
不适用
A Pilot Study to Evaluate the Safety and Effectiveness of Microneedling and Bellafill to Treat Facial Acne ScarsAtrophic Acne ScarsNCT02643628Suneva Medical, Inc.45
已完成
1 期
Mesenchymal Stem Cells for the Treatment of COVID-19Covid19ProphylaxisNCT04573270Thomas Advanced Medical LLC40